Synapse - Jae Park

Results (356)

Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma

Journal Article

Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G.; Fregonese, B.; Wills, B.; Bedmutha, A.; Alarcon Tomas, A.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab

Review

Jabbour, E. J.; Kantarjian, H. M.; Goekbuget, N.; Shah, B. D.; Chiaretti, S.; Park, J. H.; Rijneveld, A. W.; Gore, L.; Fleming, S.; Logan, A. C.; more...
Blood Cancer Journal (2024)

Fulltext@MSK | Save

A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol

Journal Article

Palmisiano, N. D.; Lee, J. W.; Claxton, D. F.; Paietta, E. M.; Alkhateeb, H.; Park, J.; Podoltsev, N. A.; Atallah, E. L.; Schaar, D. G.; Dinner, S. N.; more...
eJHaem (2024)

Fulltext@MSK | Save

Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile

Journal Article

Shouval, R.; Goldman, A.; Flynn, J. R.; El-Moghraby, A.; Rehman, M.; Devlin, S. M.; Corona, M.; Landego, I.; Lin, R. J.; Scordo, M.; more...
British Journal of Haematology (2024)

Fulltext@MSK | Save

The role of CAR T-cell therapy in relapsed/refractory adult B-ALL

Review

Othman, T.; Logan, A. C.; Muffly, L.; Leonard, J.; Park, J.; Shah, B.; Aldoss, I.
Journal of the National Comprehensive Cancer Network (2024)

Fulltext@MSK | Save

Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma

Journal Article

Lorenc, R.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Saldia, A.; Luna De Abia, A.; De Lapuerta, M. C.; Tomas, A. A.; Cassanello, G.; Leslie, L. A.; more...
Transplantation and Cellular Therapy (2024)

Fulltext@MSK | Save

Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3

Meeting Abstract

Oluwole, O. O.; Ghobadi, A.; Cassaday, R. D.; Park, J. H.; Houot, R.; Logan, A.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study

Meeting Abstract

Jabbour, E.; Tholouli, E.; Sandhu, K. S.; Shaughnessy, P.; Barba, P.; Guerreiro, M.; Yallop, D.; Logan, A.; Abedi, M.; Lao-Sirieix, P.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify)